Pharmaceutical solid dispersions
First Claim
1. A dispersion consisting of a low-solubility drug and cellulose acetate phthalate, wherein said dispersion is formed by spray drying with a non-aqueous solvent in which said drug and said cellulose acetate phthalate are both soluble, and wherein at least 90% of said drug once dispersed in said dispersion is amorphous, said dispersion has a single glass transition temperature of at least 50°
- C. measured at 50% relative humidity, said composition provides a maximum concentration of said drug in a use environment that is at least 1.5-fold that of a control comprising an equivalent quantity of undispersed drug.
2 Assignments
0 Petitions
Accused Products
Abstract
A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100° C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50° C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment. The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.
30 Citations
3 Claims
-
1. A dispersion consisting of a low-solubility drug and cellulose acetate phthalate, wherein said dispersion is formed by spray drying with a non-aqueous solvent in which said drug and said cellulose acetate phthalate are both soluble, and wherein at least 90% of said drug once dispersed in said dispersion is amorphous, said dispersion has a single glass transition temperature of at least 50°
- C. measured at 50% relative humidity, said composition provides a maximum concentration of said drug in a use environment that is at least 1.5-fold that of a control comprising an equivalent quantity of undispersed drug.
- View Dependent Claims (2, 3)
Specification